The Retention Revolution: Travel is a significant barrier for trial participants. Moving the clinical site to the home can substantially improve retention rates.
ICH E6(R3) Readiness: Japan is preparing for the shift to updated global standards. These rules require a Quality by Design approach, emphasizing proactive quality management.
Unbroken Chain of Custody: Maintaining the stability of unapproved medicines outside a clinical setting requires precise temperature control, IoT sensors, and specialized delivery services.
Scalable Compliance: Successful trials in Japan require deep expertise in navigating the Ministry of Health, Labour and Welfare (MHLW) regulations and reaching participants across diverse locations.
Traditional site-centric models of research are encountering considerable challenges in 2026. Recruitment goals are often not met because patients find it difficult to manage the time and travel required for hospital visits. To solve this challenge directly, we have established the DHL Health Logistics network. Our 2-billion-euro investment ensures you have the GDP-certified infrastructure and specialized handling needed to reach patients anywhere. Direct-to-Patient (DtP) clinical trials effectively move the laboratory to the living room while upholding the most stringent levels of safety and compliance.
The burden of travel is a primary reason participants withdraw from clinical studies. When the trial site is relocated to the patient’s home, the probability of missed visits and screen failures is greatly reduced.
Travel Distance: Cancer trial patients travel a median of nearly 42 miles for Phase I studies.
Rural Hurdles: Participants in remote areas can face considerable travel burdens, often over 100 miles each way.
Human Connection: Our technically trained couriers serve as a professional and reliable extension of the clinical site at the participant's doorstep.
Supportive Experience: Specialised, white-glove services extend beyond simple delivery to build trust and confidence among participants.
DHL Health Logistics provides the essential professional link between your laboratory and the trial participant. We understand that a courier is often the only physical representative of the trial that a patient will interact with, and we conduct ourselves with the requisite professionalism.
Regulatory bodies in Japan, such as the Ministry of Health, Labour and Welfare (MHLW), are carefully adapting their frameworks to support decentralized clinical trial models. The new ICH E6(R3) guidelines will require sponsors to provide verifiable proof that the investigational product remained stable from the depot to the patient’s refrigerator.
Regulatory Alignment: Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is actively involved in the development of ICH guidelines, indicating a structured approach to adoption.
Strict Accountability: The MHLW places a strong emphasis on quality assurance, meaning that precise and complete temperature records are a fundamental requirement.
Thermal Protection: Advanced shippers are essential for maintaining strict temperature ranges, such as 2 to 8°C or -20°C, for up to 120 hours, ensuring product integrity upon arrival at key international gateways, such as Narita International Airport, and during final delivery.
Digital Proof: IoT sensors can transmit live data, providing a verifiable record of when a participant received the shipment and confirming that the temperature remained within specification throughout its journey.
Our investment in digital tools ensures you have a complete thermal audit trail. This level of transparency is a prerequisite for satisfying the rigorous quality assurance standards expected by Japanese regulators in 2026.
The delivery of unapproved medicines to a private address is a strictly regulated activity in every market, including Japan. Success requires a partner who possesses a thorough understanding of the Pharmaceutical and Medical Device Act and the specific ordinances issued by the MHLW.
Precise Valuation: To ensure smooth passage through Japan Customs, it is critical that all documentation, particularly the commercial invoice, reflects the correct transaction value. Any perceived undervaluation can lead to significant delays and audits.
Navigating Ordinances: Our local specialists work closely with regulatory authorities to ensure that every shipment complies with the latest requirements for clinical trial materials.
Expert Navigation: We have the expertise to manage the complexities of import and delivery, ensuring your trial remains on schedule.
Expanded Footprint: Proper licensing and regulatory adherence allow you to include participants from a wider geographic area, including those in less accessible regions, which was previously considered too complex.
Security and privacy are of the utmost importance when delivering sensitive medical products to a private residence. It is imperative to ensure the medicine is handed directly to the verified participant or their legally designated representative.
Identity Verification: We perform rigorous identity checks against trial records before any package is handed over.
Point-of-Use Delivery: When required, our couriers can place the medication directly into the participant’s designated storage area or refrigerator.
Instruction Support: We confirm that the patient understands how to correctly handle the specialized packaging.
Safe Disposal: Our service includes the collection of used kits or sharp containers for proper, medical-grade destruction, closing the logistics loop securely.
A DtP trial is not complete upon delivery. It is equally important to manage the return flow of biological samples and any unused investigational products back to the central laboratory with precision.
Stability Windows: Biological samples, such as blood or urine, must be collected and returned to the laboratory within strictly defined time and temperature parameters.
Data Integrity: If a sample deviates from its required temperature range during transit, the integrity of the resulting trial data may be compromised.
Remote Reach: We utilise specialised transport solutions to reliably collect samples from participants across Japan, from major urban centres to more remote locations.
Unified Visibility: A clinical research associate in Tokyo should have access to the exact same tracking data as a sponsor in Europe, ensuring global consistency.
Direct-to-Patient logistics has transitioned from a future concept to a practical necessity. It represents a superior method for enhancing the patient experience and safeguarding the integrity of your data. DHL Health Logistics is prepared to assist you in scaling your research throughout Japan and the wider APAC region. We invite you to speak with a DHL specialist today to review your trial plan and reach your participants with confidence.
They remove the significant physical burden of travel by arranging for the delivery of investigational medicine directly to the participant's home. This makes it far more manageable for patients to adhere to the study protocol while maintaining their daily routines.
These 2026 guidelines will require sponsors to implement a Quality by Design approach. This means you must possess digital, verifiable proof that your investigational products were maintained under stable conditions throughout the entire journey to the patient.
We employ real-time IoT sensors that transmit live location and thermal data to a central dashboard. This system ensures that you receive an immediate alert if the shipment deviates from its pre-defined temperature range.
Yes, though it requires a partner with demonstrated expertise in handling the specific local medical licenses and import regulations in each country. Utilising a standardized digital platform like MyDHL+ ensures your data remains consistent and comparable across diverse markets like Japan.
Yes, our couriers follow a strict, verified delivery protocol. This procedure includes checking the participant's official identification to ensure the sensitive medication is handed over exclusively to the correct, authorized person.
Share
